TISIDB

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF00084 Sushi repeat (SCR repeat) PF00089 Trypsin PF00092 von Willebrand factor type A domain
Function	Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.

> Gene Ontology [ TOP ]
Biological Process	GO:0002526 acute inflammatory response GO:0002673 regulation of acute inflammatory response GO:0002697 regulation of immune effector process GO:0002920 regulation of humoral immune response GO:0006956 complement activation GO:0006957 complement activation, alternative pathway GO:0006959 humoral immune response GO:0016485 protein processing GO:0030449 regulation of complement activation GO:0050727 regulation of inflammatory response GO:0051604 protein maturation GO:0070613 regulation of protein processing GO:0072376 protein activation cascade GO:1903317 regulation of protein maturation GO:2000257 regulation of protein activation cascade
Molecular Function	GO:0001848 complement binding GO:0004175 endopeptidase activity GO:0004252 serine-type endopeptidase activity GO:0008236 serine-type peptidase activity GO:0017171 serine hydrolase activity
Cellular Component	GO:0072562 blood microparticle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04610 Complement and coagulation cascades
Reactome	R-HSA-174577: Activation of C3 and C5 R-HSA-173736: Alternative complement activation R-HSA-166658: Complement cascade R-HSA-168256: Immune System R-HSA-166663: Initial triggering of complement R-HSA-168249: Innate Immune System R-HSA-977606: Regulation of Complement cascade

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CFB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CFB in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CFB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.411	0.494
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.854	0.425
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.359	0.0712
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.022	0.028
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.666	0.761
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.475	0.605
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.924	0.215
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.512	0.261
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.031	0.986
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.44	0.871
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.73	0.859
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.127	0.606

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CFB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	18.5	5.5	13	0.0572
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	18.5	6.8	11.7	0.132
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CFB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CFB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CFB. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CFB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CFB expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CFB and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CFB
Name	complement factor B
Aliases	H2-Bf; BF; B-factor, properdin; AHUS4; CFABD; FBI12; GBG; PBF2; C3 proaccelerator; C3 proactivator; glycine- ......
Chromosomal Location	6p21.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CFB collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CFB.

ID	Name	Drug Type	Targets	#Targets
DB01593	Zinc	Small Molecule	A1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......	119
DB02459	4-Guanidinobenzoic Acid	Small Molecule	CFB	1
DB04491	Diisopropylphosphono Group	Small Molecule	CFB, DPP4	2

Browse CFB